Skip to main content

Critical Care Reviews Newsletter

Newsletter 562  |  September 18th, 2022

Please support our work to share science

Lars Andersen presents the VAM-IHCA trial at CCR22

Welcome to the 562nd Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature over the past seven days.

The highlights of this week's edition are randomised controlled trials evaluating fluid resuscitation in acute pancreatitis & remote ischemic conditioning in septic shock; systematic reviews and meta analyses on vasopressin during cardiopulmonary resuscitation & vasoactive treatments for hepatorenal syndrome; and observational studies on the differential response to convalescent plasma in critically ill patients with COVID-19 & respiratory support in patients with severe COVID-19.

There are also guidelines on palliative care early in the care continuum among patients with serious respiratory illness & severe acute pancreatitis; narrative reviews on indications and timing of initiation of KRT & critical illness and bone metabolism; commentaries on source control in the management of sepsis and septic shock & the glycocalyx as a permeability barrier. There is also a fantastic series from Anaesthesia on "Emergencies in Anaesthesia".

If you only have time to read one review article this week, try this one on the end of “One Size Fits All” sepsis therapies: toward an individualized approach.

The latest video to be released from CCR22 is the VAM-IHCA trial presentation by Lars Andersen, from Aarhus, Denmark. This ties in beautifully with this week's visual abstract from Jakub Fronczek, which is also on the VAM-IHCA trial. Follow us on Instagram to stay current with these superb infographics.

Support CCR

You can support Critical Care Reviews, from as little as the price of a cup of coffee per month or make a one-off donation. We are not-for-profit and make all our content free to view. Our aim is to share science for the benefit of all - please join us in this mission.

I hope you find this newsletter useful.


Until next week

Rob